Table 2.

Frequency of CTSL, 53BP1, and VDR expression within molecular subtype relative to the median values in sporadic human breast cancer

Proteins Molecular type n (%) Fisher exact test p-value 
Nuclear CTSL >0 Luminal A 23 (23.2) 0.0013 
 Luminal B 22 (31.9)  
 Erbb2 (−1) 12 (27.3)  
 Triple negative (−1) 21 (60.0)  
53BP1 <150 Luminal A 59 (59.6) 0.0049 
 Luminal B 35 (50.7)  
 Erbb2 (−4) 21 (51.2)  
 Triple negative 9 (25.0)  
Nuclear VDR <120 Luminal A 46 (48.4) 0.34 
 Luminal B 40 (61.5)  
 Erbb2 (−4) 25 (58.1)  
 Triple negative 16(48.5)  
Proteins Molecular type n (%) Fisher exact test p-value 
Nuclear CTSL >0 Luminal A 23 (23.2) 0.0013 
 Luminal B 22 (31.9)  
 Erbb2 (−1) 12 (27.3)  
 Triple negative (−1) 21 (60.0)  
53BP1 <150 Luminal A 59 (59.6) 0.0049 
 Luminal B 35 (50.7)  
 Erbb2 (−4) 21 (51.2)  
 Triple negative 9 (25.0)  
Nuclear VDR <120 Luminal A 46 (48.4) 0.34 
 Luminal B 40 (61.5)  
 Erbb2 (−4) 25 (58.1)  
 Triple negative 16(48.5)  

Values denote the absolute (n) and the relative (%) frequencies of tumors with Hscore values above (nuclear CTSL) or below (nuclear 53BP1 and VDR) the median Hscore values for each protein in the overall population of sporadic breast cancer. Bolded frequency values highlight the molecular subtype responsible for the statistically significant difference identified with the Fisher exact test that compares all molecular types (bold p-value if significant difference).

or Create an Account

Close Modal
Close Modal